Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

Yoon K. Loke MBBS MD, Sonal Singh MD MPH, Curt D. Furberg MD PhD

Published at www.cmaj.ca on Dec. 10, 2008.

See related commentary by Lipscombe, page 16

Abstract

Background: Rosiglitazone and pioglitazone may increase the incidence of fractures. We aimed to determine systematically the risk of fractures associated with thiazolidinedione therapy and to evaluate the effect of the therapy on bone density.

Methods: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), other trial registries and product information sheets through June 2008. We selected long-term (≥1 year) randomized controlled trials involving patients with type 2 diabetes and controlled observational studies that described the risk of fractures or changes in bone density with thiazolidinediones. We calculated pooled odds ratios (ORs) for fractures and the weighted mean difference in bone density.

Results: We analyzed data from 10 randomized controlled trials involving 13 715 participants and from 2 observational studies involving 31 679 participants. Rosiglitazone and pioglitazone were associated with a significantly increased risk of fractures overall in the 10 randomized controlled trials (OR 1.45, 95% confidence interval [CI] 1.18–1.79; p < 0.001). Five randomized controlled trials showed a significantly increased risk of fractures among women (OR 2.23, 95% CI 1.65–3.01; p < 0.001) but not among men (OR 1.00, 95% CI 0.73–1.39; p = 0.98). The 2 observational studies demonstrated an increased risk of fractures associated with rosiglitazone and pioglitazone. Bone mineral density in women exposed to thiazolidinediones was significantly reduced at the lumbar spine (weighted mean difference −1.11%, 95% CI −2.08% to −0.14%; p = 0.02) and hip (weighted mean difference −1.24%, 95% CI −2.34% to −0.67%; p < 0.001) in 2 randomized controlled trials.

Interpretation: Long-term thiazolidinedione use doubles the risk of fractures among women with type 2 diabetes, without a significant increase in risk of fractures among men with type 2 diabetes.

Recent systematic reviews have focused on the adverse cardiovascular effects of the thiazolidinediones rosiglitazone and pioglitazone.1–5 In late 2006, the risk of fractures with the use of rosiglitazone was raised in a footnote of the report of the A Diabetes Outcome and Progression Trial (ADOPT).6 The manufacturers of rosiglitazone7 and pioglitazone followed this up by issuing warning letters about the risk of fractures.7,8

Women with type 2 diabetes are at an increased risk of non-vertebral fractures,9 with a near doubling in the risk of hip fractures.10 Any additional risk from thiazolidinedione therapy could have a considerable impact. Our primary objective was to determine systematically the relative and absolute risks of fractures with long-term thiazolidinedione therapy for type 2 diabetes. We also reviewed the effect of thiazolidinedione therapy on bone mineral density to ascertain its biological plausibility.

Methods

Search strategy

We searched MEDLINE, EMBASE and the Cochrane Central Registry of Controlled Trials (CENTRAL) through June 2008. We also searched the websites of regulatory authorities, manufacturers’ product information sheets, and the registers of clinical trials of GlaxoSmithKline,12 Takeda Pharmaceuticals,13 and the Clinical Study Results database14 for unpublished studies. We checked existing systematic reviews and the bibliographies of the studies that were included. Finally, we used the Web of Science Citation Index to identify relevant articles of high impact. Our search strategy is outlined in Appendix 1 (available at www.cmaj.ca/cgi/content/full/180/1/32/DC2).

Eligibility criteria

We selected randomized controlled trials and controlled observational studies that compared the risk of fracture among patients with type 2 diabetes who were taking thiazolidinedione therapy and patients not taking this therapy.

We included randomized controlled trials that met the following inclusion criteria: parallel-design trial of any thiazolidinedione (rosiglitazone, pioglitazone or troglitazone) of at least one year’s duration. The participants had impaired glucose tolerance or type 2 diabetes mellitus; each study used either placebo or oral therapy with an active comparator as the control arm; the treatment groups differed only in the use of thiazolidinedione therapy; the placebo or oral therapy with an active comparator as the control arm; the treatment groups differed only in the use of thiazolidinedione therapy and patients not taking this therapy.
thiazolidinediones; and the studies reported clearly on fracture outcomes.

For the secondary outcome of effects of thiazolidinediones on bone mineral density, we selected randomized controlled trials and controlled observational studies of any duration that compared changes in bone mineral density in patients with and without thiazolidinedione exposure.

Validity assessment
We assessed the reporting of allocation concealment and the use of blinding in the randomized controlled trials. In accordance with the Cochrane handbook for systematic reviews of interventions, we assessed the strength of data on adverse effects in both the randomized controlled trials and the observational studies by noting how the investigators monitored and recorded adverse effects.15

Data abstraction
Two reviewers (Y.K.L and S.S.), both independently and as a team, assessed the eligibility and quality of studies for reporting of adverse events. They extracted numerical data on outcomes from the studies included in our analysis. The reviewers achieved consensus on inclusion of the studies and data extraction. Any discrepancies were resolved through discussion. They also contacted authors about items that required clarification.

Study characteristics
From the randomized controlled trials, we recorded the dose and duration of thiazolidinedione therapy and the baseline characteristics of the participants. From the observational studies, we recorded information on the sources of data, the participants, the verification of exposure and the outcomes.

Data synthesis
We used fixed-effects models to calculate pooled odds ratios (ORs), with 95% confidence intervals (CIs), for dichotomous outcomes. We calculated weighted mean differences for continuous outcomes. The fixed-effects Mantel–Haenszel model is the appropriate method for meta-analysis of rare events.16 All reported p values are 2-sided, with significance set at p less than 0.05. Statistical heterogeneity was assessed using the I² statistic, with 95% CIs.17,18 A substantial level of heterogeneity is indicated by I² values of 50% or more.17

We also carried out a predefined sensitivity analysis to determine the influence of trial duration and statistical models on effect size. We estimated the fail-safe number using the Rosenberg method to assess the potential impact of missing data in the meta-analysis (i.e., the number of additional negative trials that would be required to reverse a significant finding in the meta-analysis).19

We calculated the number needed to harm by applying the pooled OR from the meta-analysis to the control event rate in different populations.20,21 The number needed to harm is the number of patients with type 2 diabetes who must be treated with a thiazolidinedione (rather than another intervention) for 1 additional patient to have a fracture. To account for variation in follow-up, we calculated the number needed to harm using person-years as denominators.22

Results
The selection of trials is summarized in Figure 1. Overall, 10 randomized controlled trials involving a total of 13 715 participants reported on fractures.23–32 All of the trials were double-blinded. We judged allocation concealment to be adequate in 6 trials23,24,27,30,32 and unclear in 4 trials.26,28,29,31 All of the trials included participants with impaired glucose tolerance31 and type 2 diabetes.23–32 The duration was from 1 to 4 years.23 Data on fractures were available by sex in 5 trials.23,24,30,32 The participants in the treatment groups were similar to the control patients with respect to ethnic background, disease duration, glycosylated hemoglobin and body mass index in these 5 trials. Full descriptions of the characteristics of the 10 trials are shown in Appendix 2 (available at www.cmaj.ca/cgi/content/full/180/1/32/DC2).

Risk of fractures
Figure 2 shows the pooled data from the 10 randomized controlled trials evaluating the risk of fractures associated with thiazolidinediones overall, and by sex.

We found that thiazolidinediones significantly increased the risk of overall fractures compared with controls (OR 1.45, 95% CI 1.18–1.79; p < 0.001); the statistical heterogeneity was moderate (I² = 27%) (Figure 2A).
The pooled data from the 5 trials that reported fracture risk by sex (4400 women, 7001 men) showed that thiazolidinediones significantly increased the risk of fractures among women compared with controls (OR 2.23, 95% CI 1.65–3.01; p < 0.001) (Figure 2B); there was no statistical heterogeneity among the included trials (I² = 0%). Thiazolidinediones did not significantly increase the risk of fractures among men (OR 1.00, 95% CI 0.73–1.39; p = 0.98; F = 0%) (Figure 2C). Statistical testing for interaction confirmed a significant difference between the male and female subgroups (χ² 12.01, p < 0.001).

The characteristics of the 2 observational studies that reported on the association between thiazolidinedione exposure and fractures are shown in Appendix 3 (available at www.cmaj.ca/cgi/content/full/180/1/32/DC2). The case–control study by Meier and colleagues showed a significant association between thiazolidinedione exposure (current users with > 8 prescriptions) and fractures among women (OR 2.56, 95% CI 1.43–4.58). In the cohort study, rosiglitazone was significantly associated with fractures when compared with women taking metformin (OR 1.38, 95% CI 1.03–1.82), but no signifi-

A. Fractures overall

| Study                  | No. of fractures | Thiazolidinedione | Control   | Odds ratio (95% CI)       |
|------------------------|------------------|-------------------|-----------|---------------------------|
| Kahn et al.            | 92/1456          | 108/2895          | 1.74 (1.31–2.32) |
| Dormandy et al.        | 74/2605          | 60/2633           | 1.25 (0.89–1.77) |
| AVM100264 trial        | 2/294            | 1/301             | 2.05 (0.19–22.78) |
| GSK49653 334 trial     | 0/277            | 3/278             | 0.14 (0.01–2.76) |
| GSK49653 351 trial     | 0/30             | 1/30              | 0.32 (0.01–8.24) |
| Jain et al.            | 0/251            | 2/251             | 0.20 (0.01–4.15) |
| Nissen et al.          | 8/270            | 0/273             | 17.71 (1.02–308.42) |
| DeFronzo et al.        | 8/303            | 8/299             | 0.99 (0.37–2.66) |
| Seufert et al. (a)     | 1/317            | 1/313             | 0.99 (0.06–15.85) |
| Seufert et al. (b)     | 0/319            | 2/320             | 0.20 (0.01–4.17) |
| Overall (95% CI)       | 185/6122         | 186/7593          | 1.45 (1.18–1.79) |

B. Fractures in women

| Study                  | No. of fractures | Thiazolidinedione | Control   | Odds ratio (95% CI)       |
|------------------------|------------------|-------------------|-----------|---------------------------|
| Dormandy et al.        | 44/870           | 23/905            | 2.04 (1.22–3.41) |
| Kahn et al.            | 60/645           | 51/1195           | 2.30 (1.56–3.39) |
| Nissen et al.          | 6/84             | 0/93              | 15.48 (0.86–279.18) |
| Seufert et al. (a)     | 1/156            | 1/159             | 1.02 (0.06–16.44) |
| Seufert et al. (b)     | 0/148            | 1/145             | 0.32 (0.01–8.03) |
| Overall (95% CI)       | 111/1903         | 76/2497           | 2.23 (1.65–3.01) |

C. Fractures in men

| Study                  | No. of fractures | Thiazolidinedione | Control   | Odds ratio (95% CI)       |
|------------------------|------------------|-------------------|-----------|---------------------------|
| Dormandy et al.        | 30/1735          | 37/1728           | 0.80 (0.49–1.31) |
| Kahn et al.            | 32/811           | 57/1700           | 1.18 (0.76–1.84) |
| Nissen et al.          | 2/186            | 0/180             | 4.89 (0.23–102.60) |
| Seufert et al. (a)     | 0/161            | 0/154             | Not estimable |
| Seufert et al. (b)     | 0/171            | 1/175             | 0.34 (0.01–8.38) |
| Overall (95% CI)       | 64/3064          | 95/3937           | 1.00 (0.73–1.39) |

Figure 2: Meta-analysis of fractures in randomized controlled trials of thiazolidinedione versus control.
Sensitivity analyses
The sensitivity analysis using a random-effects model yielded estimates similar to those of the fixed-effects model for the risk of fractures associated with thiazolidinedione exposure and fractures among women (OR 2.19, 95% CI 1.62–2.97; p < 0.001). Overall fractures (OR 1.32, 95% CI 0.91–1.92) and fractures among men (OR 1.00, 95% CI 0.73–1.39) were not statistically significant in the sensitivity analysis.

The sensitivity analysis based on the 6 longer-term randomized controlled trials (18 months to 4 years) showed an elevated risk of fracture (OR 1.51, 95% CI 1.18–1.79; p < 0.001). The sensitivity analysis of the 4 smaller trials of 12 months’ duration showed a nonsignificant risk of fracture (OR 0.41, 95% CI 0.12–1.44; p = 0.16).

Similarly, the association with fractures in the case–control study became apparent among patients who received more than 8 thiazolidinedione prescriptions (corresponding to about 12–18 months of therapy). The cohort study enrolled 27,000 patients with 30,600 patient-years of follow-up, which indicated that, on average, participants were exposed for just over a year. With this relatively short duration of exposure, the OR for the rosiglitazone–metformin comparison was elevated only moderately at 1.38, and no significant association was seen in the rosiglitazone–sulfonylurea comparison.

To reverse the significantly increased risk of fractures among women shown in our meta-analysis, we estimated that 42 negative studies with an average sample size of 880 women each would be required.  

Change in bone mineral density
We identified 2 relevant randomized controlled trials and 2 observational studies (Table 1). All 4 studies showed a consistent decline in bone mineral density associated with thiazolidinediones compared with controls.

The meta-analysis of the percentage point change in bone mineral density in both trials among women who used thia-
zolidinediones showed a significant reduction at the lumbar spine (weighted mean difference −1.11%, 95% CI −2.08% to −0.14%; p = 0.02; F = 0%) and at the hip (weighted mean difference −1.24% (95% CI −2.34% to −0.67%; p < 0.001; F = 0%). Adding the observational data from the study by Yaturu and colleagues37 yielded similar findings at the lumbar spine (weighted mean difference −1.36%, 95% CI −2.05% to −0.67%; p = 0.001; F = 0%) and at the hip (weighted mean difference −1.24%, 95% CI −1.78% to −0.70%; p < 0.001; F = 0%) compared with controls (Figure 3).

We excluded 1 observational study from the meta-analysis because its outcome data were reported in a different format.38

**Estimated number needed to harm**

The relative risk of fractures with thiazolidinediones remained consistently elevated irrespective of age33 or menopausal status of women.23 Therefore, we used the single pooled relative risk to estimate the number needed to harm across different age groups.39 Table 2 shows the variation in the number needed to harm and the number of excess fractures with different baseline populations. The patient populations ranged from patients with newly diagnosed type 2 diabetes at low risk of fractures who were in the metformin arm of the ADOPT study (number needed to harm 55, 95% CI 34–103)33 to older postmenopausal women with type 2 diabetes at high risk of fracture (number needed to harm 21, 95% CI 14–39).40

**Interpretation**

Our meta-analysis showed that the long-term use of thiazolidinediones doubles the risk of fractures among women with type 2 diabetes, without a significant increase in risk of fractures among men with type 2 diabetes. Overall, use of thiazolidinediones significantly increased the risk of fractures among patients with type 2 diabetes. Thiazolidinedione exposure was also associated with significant changes in bone mineral density at the lumbar spine and the hip. A posthoc analysis of fracture risk with rosiglitazone in the ADOPT study failed to show any clear relation to ethnicity, hypoglycemia, weight gain or age.21 However, thiazolidinediones may cause fractures by increasing adiposity of bone marrow, decreasing osteoblast activity or reducing aromatase activity,

| A. Lumbar spine | Treatment | Control | Mean difference (95% CI) |
|-----------------|-----------|---------|-------------------------|
| Study or subgroup | Mean % change (SD) | n | Mean % change (SD) | n |
| Randomized controlled trial |          |       |                        |
| Glintborg et al.34 | −1.02 (2.66) | 30 | 0.34 (2.78) | 14 | −1.36 (–3.10 to 0.38) |
| Grey et al.35 | −1.2 (2.1) | 25 | −0.2 (2.1) | 25 | −1.00 (–2.16 to 0.16) |
| Subtotal | 55 | 39 | −1.11 (–2.08 to –0.14) |
| Observational study |          |       |                        |
| Yaturu et al.37 | 0.69 (2.4) | 32 | 2.3 (2.9) | 128 | −1.61 (–2.58 to –0.64) |
| Subtotal | 32 | 128 | −1.61 (–2.58 to –0.64) |
| Overall | 87 | 167 | −1.36 (–2.05 to –0.67) |

| B. Hip | Treatment | Control | Mean difference (95% CI) |
|--------|-----------|---------|-------------------------|
| Study or subgroup | Mean % change (SD) | n | Mean % change (SD) | n |
| Randomized controlled trial |          |       |                        |
| Glintborg et al.34 | −0.41 (2.03) | 30 | 0.67 (2.46) | 14 | −1.08 (–2.56 to 0.40) |
| Grey et al.35 | −1.9 (2) | 25 | −0.2 (1.6) | 25 | −1.70 (–2.70 to –0.70) |
| Subtotal | 55 | 39 | −1.50 (–2.34 to –0.67) |
| Observational study |          |       |                        |
| Yaturu et al.37 | −1.19 (1.8) | 32 | −0.14 (1.9) | 128 | −1.05 (–1.76 to –0.35) |
| Subtotal | 32 | 128 | −1.05 (–1.76 to –0.35) |
| Overall | 87 | 167 | 1.24 (–1.78 to –0.70) |

Figure 3: Change in bone mineral density in trials and observational studies.
each of which alters estrogen production and increases bone resorption. Thiazolidinediones have a negative effect on markers of bone formation such as alkaline phosphatase and parathyroid hormone. In rodent models, rosiglitazone was found to decrease osteoblastic function, which led to bone loss. Thiazolidinediones may also promote osteoclast differentiation and bone resorption. No proven strategies exist for reducing the risk of fractures induced by thiazolidinediones. Elderly postmenopausal women with type 2 diabetes may not be protected by bisphosphonate therapy.

The underlying mechanism for the apparent sex-specific effect of thiazolidinediones needs further investigation. In animal studies, bone loss occurred with rosiglitazone treatment in rats that had their ovaries removed, but not in rats that were intact. This indicated that higher levels of sex steroids may protect against fractures in men.

The predominance of fractures in the upper and distal lower limbs with thiazolidinedione therapy, with the relative paucity of hip fractures in the trials, may be attributed to the age of the participants (the mean age was 56 years in the ADOPT study). In the observational study by Sanders and colleagues, the most commonly found fractures in people 55–64 years of age were in the distal upper and lower limbs, whereas the majority (92%) of hip fractures occurred in women over 75 years. The low baseline incidence of hip fractures in the trials’ relatively young participants means that the trials lacked the power to detect any significant increase in hip fracture risk (Appendix 4, available at www.cmaj.ca/cgi/content/full/180/1/32/DC2). However, the case–control study involving an older female population (60% were over 60 years) showed that fractures of the hip and femur were significantly associated with thiazolidinedione therapy (OR 4.54, 95% CI 1.28–16.10).

The public health impact may be considerable. There were more than 4 million individual users of thiazolidinediones in the United States in 2006. If one assumes that half of those users were women and that the baseline risk of fractures is similar to that found in the ADOPT study, an estimated 30 000 excess fractures may have occurred if these women had been prescribed thiazolidinediones rather than metformin for more than a year. The excess number of fractures with thiazolidinediones would be 3-fold higher if they experienced fractures at the rates found in population studies rather than at the conservative levels of baseline risk levels of the trials. There is no clear evidence that other oral hypoglycemic agents such as metformin and the sulfonylureas are associated with an increased risk of fractures. Previous observational studies have suggested an increased risk of fracture associated with insulin use, likely due to confounding by severity and duration of diabetes and the presence of comorbidities.

Our results highlight the failure of pharmacovigilance mechanisms that rely on follow-up of spontaneous reports. We found only a handful of reports of fracture with thiazolidinedione use in the databases of the US Food and Drug Administration in 2006 and Health Canada in 2006. However, in 2001, Quesada-Gomez and Serrano-Alferez had already called for randomized trials to “examine changes in bone mass and risk for fractures.” Moreover, Rzonca and colleagues had warned in 2004 that “rosiglitazone therapy may pose a significant risk of adverse skeletal effects in humans.”

**Limitations**

Our meta-analysis has several limitations, which are mainly due to the paucity of reported data. None of the trials included was prospectively designed to measure the risk of fractures. Nevertheless, incidence rates of fractures in the control arms of the trials were consistent with those found in large-scale epidemiologic studies. We did not have sufficient data to determine whether the risk varied with the particular drug or with different fracture sites. Our estimates of the number needed to harm are valid only for women receiving more than 12 months of thiazolidinedione therapy within the context of specific populations.

We excluded 17 long-term trials of at least 12 months’ duration from our analysis because they did not report fracture rates. Although they are unlikely to reverse the direction of

---

**Table 2: Number needed to harm and number of excess fractures in different populations of women with type 2 diabetes mellitus taking thiazolidinediones**

| Population | Baseline risk of fractures per 1000 patient-years | Odds ratio of fracture (95% CI) from meta-analysis | 1-year number needed to harm* (95% CI) | Excess fractures with thiazolidinedione use per 1000 patient-years (95% CI) |
|------------|-----------------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------------------|
| Women in the metformin arm of the ADOPT study; mean age 56 years; diabetes diagnosed within 3 years before study; no previous use of oral hypoglycemic agent | 15.4 | 2.23 (1.65–3.01) | 55 (34–103) | 18 (10–29) |
| Elderly postmenopausal women in Women’s Health Initiative Observational Study; mean age 65 years | 28.6 | 2.23 (1.65–3.01) | 31 (19–57) | 32 (18–53) |
| Older cohort of women with diabetes not using insulin; mean age 72 years | 43.5 | 2.23 (1.65–3.01) | 21 (14–39) | 48 (26–71) |

Note: ADOPT = A Diabetes Outcome and Progression Trial.

*Number of patients with type 2 diabetes who must be treated with a thiazolidinedione, rather than another intervention, for 1 additional patient to have a fracture.
statistical significance of the effect, they may alter the precision of the risk and the confidence intervals. However, not all of the currently unavailable data are negative. An independent interim analysis of fractures in a large long-term rosiglitazone trial that is underway has yielded similar results to those of the ADOPT study.7

The only available data from randomized controlled trials on reduced bone mineral density were from healthy women3 and participants with polycystic ovary syndrome,4 rather than patients with type 2 diabetes. However, women with diabetes are likely at similar risk, as shown in the observational studies.8

Conclusion
Despite their limitations, our findings have potential regulatory and clinical implications. Only limited evidence exists that thiazolidinedione-induced glycemic control leads to any reduction in the complications of diabetes.3,5 The relatively modest benefits of thiazolidinediones must be balanced against their significant long-term effects on bone and the cardiovascular system. Clinicians should reconsider the use of thiazolidinediones in women with type 2 diabetes. This is in accordance with the updated guidelines of the United Kingdom National Institute of Clinical Excellence.6 The guidelines state: “Do not commence or continue a thiazolidinedione in people who have evidence of heart failure, or who are at higher risk of fracture.” Regulatory agencies should restrict the use of thiazolidinediones in women with diabetes who are at risk for fractures.

This article has been peer reviewed.

Competing interests: Curt Furberg is a senior investigator and steering committee chair of the National Health, Lung, and Blood Institute–sponsored Cardiovascular Health Study (CHS), a cohort study to examine risk factors of coronary artery disease and stroke in elderly people. In 2004, the study received a grant for $280 000 from GlaxoSmithKline to determine the relations between LpPLA-2 and various vascular diseases. The grant was primarily for the CHS central laboratory and the CHS coordinating centre. Funding was channelled through Wake Forest University, and Dr. Furberg was the CHS principal investigator. He received no salary support and the funding period ended June 30, 2006. Dr. Furberg has no funding from any other manufacturer or other entity of antidiabetic medications. Yoon Loke and Sonal Singh have no competing interests to declare.

Contributors: Yoon Loke and Sonal Singh conceptualized the review, developed the protocol, abstracted and analyzed the data and wrote the manuscript. Curt Furberg reviewed the draft, interpreted the data and provided critical input. Yoon Loke will act as the guarantor for the paper. All of the authors approved the final version of the manuscript submitted for publication.

Funding: No external funding was received for this research.

REFERENCES
1. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95.
2. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleology analysis. Diabetes Care 2007;30:2148-53.
3. Lincoff AM, Wolski K, Nichols SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8.
4. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trials. Lancet 2007;370:1129-36.
5. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
6. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [erratum in N Engl J Med 2007;356:1387-8]. N Engl J Med 2006;355:2427-34.
7. Clinical trial observation of long-term use and coronary artery disease in females in patients who received long-term treatment with Avandia® (rosiglitazone maleate) tablets for type 2 diabetes mellitus [Dear Health Care Provider letter]. Philadelphia (PA): GlaxoSmithKline; 2007. Available: www.fda.gov/medwatch/safety/2007/Avandia/Avandia_Lir.pdf (accessed 2008 Jul 13).
8. Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone hydrochloride) tablets for type 2 diabetes mellitus [Dear Health Care Provider letter]. Dearfield (IL): Takeda Pharmaceuticals North America; 2007. Available: www.fda.gov/MEDWATCH /SAFETY/2007/Actosmar0807.pdf (accessed 2008 Jul 13).
9. Increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone hydrochloride) tablets for type 2 diabetes mellitus. Toronto (ON): Eli Lily Canada Inc.; 2007. Available: www.he-wc.ca/dfp-mps /meded/advisories-avip/prod/2007/actos_hpc-cps_e2.html (accessed 2008 Jul 13).
10. Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study. J Clin Endocrinol Metab 2005;90:3540-6.
tients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-73.

31. DeFronzo RA. Actos Now for Prevention of Diabetes (ACT NOW). NCT00220961. Proceedings of the American Diabetes Association 68th Scientific Sessions: Late Breaking Clinical Studies. 2008 Jun 6–10; San Francisco. Alexander V (Chair). The American Diabetes Association; 2008.

32. Seufert J, Uqahart R. 2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes. Diabetes Res Clin Pract 2008;79:453-60.

33. Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008;168:820-5.

34. Fracture diagnoses in patients receiving monotherapy with antidiabetic agents, including hand and foot fractures [study no WEUSRTP2181]. Brentford (UK): GlaxoSmithKline; 2008. Available: http://ctr.gsk.co.uk/Summary/rosiglitazone/studylist.asp (accessed 2008 Jul 13).

35. Grey A, Bolland M, Gambble G, et al. The peroxisome proliferator-activated receptor-γ (gamma) agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007;92:1305-10.

36. Glinborg D, Andersen M, Hagen C, et al. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2008;93:1696-701.

37. Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;4:CD006060.

38. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone mineral density response to bisphosphonates in late postmenopausal osteoporosis. J Bone Miner Res 2007;22:3523-30.

39. Ali R, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008;168:820-5.

40. Fracture diagnoses in patients receiving monotherapy with antidiabetic agents, including hand and foot fractures [study no WEUSRTP2181]. Brentford (UK): GlaxoSmithKline; 2008. Available: http://ctr.gsk.co.uk/Summary/rosiglitazone/studylist.asp (accessed 2008 Jul 13).

41. Berberoglu Z, Gursoy A, Bayraktar N, et al. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 2007;92:3523-30.

42. Ali R, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008;168:820-5.

43. Rzonca SO, Suva LJ, Gaddy D, et al. Bone is a target for the antidiabetic compound rosiglitazone. J Endocrinol 2006;191:3349-50.

44. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4.

45. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone mineral density response to bisphosphonates in late postmenopausal osteoporosis. J Bone Miner Res 2007;22:3523-30.

46. Lane DP, Dewey M, Amlot R, et al. Pioglitazone for type 2 diabetes mellitus: a meta-analysis. Diabetes Care 2008;31:199-203.

47. Forsen L, Meyer HE, Midthjell K, et al. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia 1999;42:920-5.

48. Sanders KM, Seerman E, Ugioni AM, et al. Age- and gender-specific rate of fracture in type 2 diabetes mellitus [review]. Cochrane Database Syst Rev 2007;3:CD006063.

49. Quesada-Gomez JM, Serrano-Alferez I. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;135:1007-8.

50. Rzonca SO, Suva LJ, Gaddy D, et al. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 2007;92:3523-30.

51. Monami M, Cresci B, Colombini A, et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care 2008;31:199-203.

52. Forces L, Meyer HE, Midthjell K, et al. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia 1999;42:920-5.

53. Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001;24:1192-7.

54. Rzonca SO, Suva LJ, Gaddy D, et al. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 2007;92:3523-30.

55. US Food and Drug Administration. Adverse event reporting system. Rockville (MD): The Administration; 2008. Available: www.fda.gov/cder/drs/default.htm (accessed 2008 Jul 13).

56. Canadian Adverse Drug Reaction Monitoring Program (CADRMP) adverse reaction database. Ottawa (ON): Health Canada; 2006. Available: www.hc-sc.gc.ca/dhp-mps/medeff/databas/databas/medeff-erpf.php (accessed 2008 Jul 13).

57. Quesada-Gomez JM, Serrano-Alferez I. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;135:1007-8.

58. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;4:CD006060.

59. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Rosiglitazone for type 2 diabetes mellitus [review]. Cochrane Database Syst Rev 2007;3:CD006063.

60. National Institute for Health and Clinical Excellence. GC66 diabetes — type 2 update: NICE guidelines. London (UK): The Institute; 2008. Available: www.nice.org.uk/Guidance/GC66/NiceGuidance/pdf/English (accessed 2008 Jul 13).

**Correspondence to:** Dr. Yoon K. Loke, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK  NR4 7TT; fax 44 1603 593752; y.loke@uea.ac.uk

---

**Product Monograph available at www.crestor.ca**

**For prescribing information see page 100**

---

**CMAJ • JANUARY 6, 2009 • 180(1)**